FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4224014734> ?p ?o ?g. }

• W4224014734 endingPage "jnumed.121.262854" @default.
• W4224014734 startingPage "jnumed.121.262854" @default.
• W4224014734 abstract "Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy movement disorder that can be imaged by the ¹⁸F-labeled tau PET tracer 2-(2-([¹⁸F]fluoro)pyridin-4-yl)-9<i>H</i>-pyrrolo[2,3-<i>b</i>:4,5-<i>c</i>′]dipyridine (¹⁸F-PI-2620). The in vivo diagnosis is currently established on clinical grounds and supported by midbrain atrophy estimation in structural MRI. Here, we investigate whether ¹⁸F-PI-2620 tau PET has the potential to improve the imaging diagnosis of PSP. <b>Methods:</b> In this multicenter observational study, dynamic (0–60 min after injection) ¹⁸F-PI-2620 PET and structural MRI data for 36 patients with PSP, 22 with PSP–Richardson syndrome, and 14 with a clinical phenotype other than Richardson syndrome (i.e., variant PSP) were analyzed along with data for 10 age-matched healthy controls (HCs). The PET data underwent kinetic modeling, which resulted in distribution volume ratio (DVR) images. These and the MR images were visually assessed by 3 masked experts for typical PSP signs. Furthermore, established midbrain atrophy parameters were measured in structural MR images, and regional DVRs were measured in typical tau-in-PSP target regions in the PET data. <b>Results:</b> Visual assessments discriminated PSP patients and HCs with an accuracy of 63% for MRI and 80% for the combination of MRI and ¹⁸F-PI-2620 PET. As compared with patients of the PSP–Richardson syndrome subgroup, those of the variant PSP subgroup profited more in terms of sensitivity from the addition of the visual ¹⁸F-PI-2620 PET to the visual MRI information (35% vs. 22%). In quantitative image evaluation, midbrain-to-pons area ratio and globus pallidus DVRs discriminated best between the PSP patients and HCs, with sensitivities and specificities of 83% and 90%, respectively, for MRI and 94% and 100%, respectively, for the combination of MRI and ¹⁸F-PI-2620 PET. The gain of sensitivity by adding ¹⁸F-PI-2620 PET to MRI data was more marked in clinically less affected patients than in more affected patients (37% vs. 19% for visual, and 16% vs. 12% for quantitative image evaluation). <b>Conclusion:</b> These results provide evidence for an improved imaging-based PSP diagnosis by adding ¹⁸F-PI-2620 tau PET to structural MRI. This approach seems to be particularly promising at earlier disease stages and could be of value both for improving early clinical PSP diagnosis and for enriching PSP cohorts for trials of disease-modifying drugs." @default.
• W4224014734 created "2022-04-19" @default.
• W4224014734 creator A5000106307 @default.
• W4224014734 creator A5001182989 @default.
• W4224014734 creator A5006871150 @default.
• W4224014734 creator A5008894116 @default.
• W4224014734 creator A5015382327 @default.
• W4224014734 creator A5018483821 @default.
• W4224014734 creator A5020744175 @default.
• W4224014734 creator A5021075936 @default.
• W4224014734 creator A5029971142 @default.
• W4224014734 creator A5034480643 @default.
• W4224014734 creator A5037230816 @default.
• W4224014734 creator A5037412930 @default.
• W4224014734 creator A5037488110 @default.
• W4224014734 creator A5041449716 @default.
• W4224014734 creator A5044480596 @default.
• W4224014734 creator A5045258788 @default.
• W4224014734 creator A5047813770 @default.
• W4224014734 creator A5048074007 @default.
• W4224014734 creator A5052236648 @default.
• W4224014734 creator A5053261811 @default.
• W4224014734 creator A5056526720 @default.
• W4224014734 creator A5057836701 @default.
• W4224014734 creator A5058052951 @default.
• W4224014734 creator A5058301976 @default.
• W4224014734 creator A5060040683 @default.
• W4224014734 creator A5060633616 @default.
• W4224014734 creator A5061631572 @default.
• W4224014734 creator A5069184646 @default.
• W4224014734 creator A5070416480 @default.
• W4224014734 creator A5071370015 @default.
• W4224014734 creator A5073170413 @default.
• W4224014734 creator A5075170885 @default.
• W4224014734 creator A5077781946 @default.
• W4224014734 creator A5083236858 @default.
• W4224014734 creator A5084033552 @default.
• W4224014734 creator A5086458638 @default.
• W4224014734 creator A5086886011 @default.
• W4224014734 date "2022-04-14" @default.
• W4224014734 modified "2023-10-16" @default.
• W4224014734 title "¹⁸F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy" @default.
• W4224014734 cites W1972291319 @default.
• W4224014734 cites W1987528617 @default.
• W4224014734 cites W1999111428 @default.
• W4224014734 cites W2005826102 @default.
• W4224014734 cites W2010846710 @default.
• W4224014734 cites W2018765794 @default.
• W4224014734 cites W2019254928 @default.
• W4224014734 cites W2030773481 @default.
• W4224014734 cites W2031224777 @default.
• W4224014734 cites W2069964327 @default.
• W4224014734 cites W2072879198 @default.
• W4224014734 cites W2083110259 @default.
• W4224014734 cites W2085875718 @default.
• W4224014734 cites W2103224436 @default.
• W4224014734 cites W2107130702 @default.
• W4224014734 cites W2117415587 @default.
• W4224014734 cites W2121046597 @default.
• W4224014734 cites W2136276906 @default.
• W4224014734 cites W2151657844 @default.
• W4224014734 cites W2152047920 @default.
• W4224014734 cites W2156821098 @default.
• W4224014734 cites W2157609814 @default.
• W4224014734 cites W2254797257 @default.
• W4224014734 cites W2294708275 @default.
• W4224014734 cites W2316856034 @default.
• W4224014734 cites W2418363880 @default.
• W4224014734 cites W2531022834 @default.
• W4224014734 cites W2537500048 @default.
• W4224014734 cites W2541769071 @default.
• W4224014734 cites W2546563765 @default.
• W4224014734 cites W2566270954 @default.
• W4224014734 cites W2582092343 @default.
• W4224014734 cites W2583390751 @default.
• W4224014734 cites W2612001459 @default.
• W4224014734 cites W2623663856 @default.
• W4224014734 cites W2625168757 @default.
• W4224014734 cites W2767134588 @default.
• W4224014734 cites W2773008621 @default.
• W4224014734 cites W2783694534 @default.
• W4224014734 cites W2794224336 @default.
• W4224014734 cites W2799400262 @default.
• W4224014734 cites W2809949958 @default.
• W4224014734 cites W2901938238 @default.
• W4224014734 cites W2917272036 @default.
• W4224014734 cites W2937277570 @default.
• W4224014734 cites W2950571742 @default.
• W4224014734 cites W2954051589 @default.
• W4224014734 cites W3038832112 @default.
• W4224014734 cites W3097325346 @default.
• W4224014734 cites W3164978586 @default.
• W4224014734 doi "https://doi.org/10.2967/jnumed.121.262854" @default.
• W4224014734 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35422444" @default.
• W4224014734 hasPublicationYear "2022" @default.
• W4224014734 type Work @default.
• W4224014734 citedByCount "7" @default.
• W4224014734 countsByYear W42240147342022 @default.

• next